Why Conventional Influenza Vaccines Fall Short

Influenza kills up to 650,000 people each year globally, yet the vaccines designed to prevent those deaths are structurally limited in ways that next-generation platforms are now specifically engineered to overcome. The core problem is twofold: conventional egg-based and recombinant vaccines depend on annual strain-prediction that is frequently wrong, and they elicit immunity almost exclusively against the highly variable head domain of hemagglutinin (HA) — the part of the virus that mutates fastest. When prediction fails, or when a pandemic strain emerges that is antigenically novel — as H5N1 and H7N9 have demonstrated — existing vaccines offer little or no protection.

Retrieved patent filings consistently frame this inadequacy as the primary motivation for next-generation development. The molecular targets addressed across the dataset reflect a deliberate pivot away from the HA head: researchers are pursuing the conserved HA stalk (HA2 subdomain), neuraminidase (NA), nucleoprotein (NP), matrix protein 2 ectodomain (M2e), and matrix protein 1 (M1) — antigens that mutate far more slowly and therefore offer the prospect of durable, cross-strain protection. According to WHO, influenza vaccine effectiveness against circulating strains varies widely season to season, underscoring the urgency of strain-independent approaches.

The patent dataset surveyed spans filings from 2009 to 2025, with activity concentrated from 2017 onward — coinciding with the maturation of mRNA-LNP technology following foundational nucleoside-modification work. Activity from academic institutions such as University of Pennsylvania and government bodies including the U.S. National Institute of Allergy and Infectious Diseases (NIAID) runs alongside commercial filings from ModernaTX, Pfizer, Sanofi, BioNTech SE, and CureVac.

The mRNA-LNP Platform: Dose Efficiency and Breadth Across Subtypes

The mRNA-lipid nanoparticle platform is the single largest modality cluster in the surveyed dataset, encompassing patents from ModernaTX, Pfizer, CureVac AG, BioNTech SE, Sanofi, and GlaxoSmithKline Biologicals SA. The mechanism involves synthetic mRNA encoding influenza antigenic polypeptides, formulated in ionizable lipid nanoparticles to enable intracellular delivery and in vivo antigen expression. The most significant technical signal in the dataset concerns dose efficiency: University of Pennsylvania patent filings describe single-dose protective immunity in murine models at 0.05 µg per antigen — compared with the 1–80 µg doses required by prior conventional mRNA influenza vaccine studies, representing a greater than 1,000-fold improvement.

“Prior influenza virus mRNA vaccine studies required doses of 1–80 µg to achieve protection in mice, while nucleoside-modified mRNA-LNP multi-antigen formulations achieved protective immunity at a single dose of 0.05 µg per antigen — a greater than 1,000-fold dose efficiency signal in preclinical models.”

Multiple ModernaTX patents specify N1-methylpseudouridine (m1Ψ) and related modified nucleosides as chemical modifications at the 5-position of uracil residues, with claims that 100% uracil substitution is preferred to reduce innate immune activation and enhance translational efficiency. LNP formulations are described with defined molar ratios of cationic lipid, non-cationic lipid, sterol, and PEG-modified lipid. ModernaTX’s broad-spectrum vaccine patents enumerate HA2 stem antigens via specific sequence ID ranges and describe consensus sequences derived from multi-subtype alignments to elicit cross-reactive seroconversion, measured by hemagglutination inhibition (HAI) titers in preclinical mammalian models.

A distinct sub-cluster within the mRNA platform focuses on valency expansion. Sanofi’s 2024 filings claim octavalent influenza vaccine compositions comprising eight mRNA species, each encoding a different influenza antigen, co-formulated in LNPs. GlaxoSmithKline Biologicals SA’s 2025 filing (Australian jurisdiction) describes a quadrivalent nucleic acid composition targeting two influenza A subtypes and two influenza B strains, with claims for immune responses against at least one further HA subtype not encoded in the composition. The University of Georgia Research Foundation’s 2025 filings claim pentavalent and octavalent compositions including HA antigens from H1, H3, and influenza B virus strains combined with NA (N1 and N2) antigens, as virus-like particles or recombinant proteins.

Universal Antigen Strategies: Targeting What the Virus Cannot Change

Universal influenza vaccine strategies bypass the annual strain-matching problem by targeting conserved viral proteins that cannot mutate freely without compromising viral fitness. The dataset reveals two parallel tracks: mRNA-encoded multi-antigen platforms and protein or peptide-based conserved antigen approaches, with more recent filing activity concentrated in the mRNA track.

HA Stalk and Chimeric Hemagglutinin Approaches

ModernaTX patents claim mRNA encoding HA2 stem antigens (enumerated via specific sequence ID ranges), citing prior literature demonstrating cross-protective antibodies against the HA stalk. The U.S. Government/NIAID filed patents on ferritin nanoparticles displaying HA trimers, with claims for protection against antigenically divergent strains — a structural biology approach in which the HA stem-only construct self-assembles around ferritin linked via trimerization domains. Icahn School of Medicine at Mount Sinai patents describe chimeric HA polypeptides designed to redirect immune responses toward conserved stalk epitopes by presenting sequential immunologically “exotic” head domains that the immune system has not previously encountered, forcing antibody responses toward the invariant stalk scaffold.

NP, M2e, and Multi-Antigen Fusion Proteins

Nucleoprotein (NP) is consistently highlighted as a conserved T cell antigen across multiple assignees. IMAXIO patents describe NP fused to a C4b-binding protein (C4bp) oligomerization domain to increase cellular immunogenicity. Texas Tech University patents claim fusion proteins combining three or more M2e ectodomain sequences from distinct influenza A strains concatenated with HA2 stem regions, demonstrating immunogenicity across strains — and notably, also claiming cross-protection against anthrax simultaneously. Emergent Product Development Gaithersburg patents describe polynucleotides encoding multiple copies of M2e peptides expressed in recombinant Modified Vaccinia Ankara (rMVA).

Computationally Optimized Consensus Antigens

Oregon Health and Science University and University of Pittsburgh patents describe computer-derived consensus HA polypeptides for H1N1, H3N2, H2N2, and influenza B, with claims for synergistic broad neutralization in prime-boost or cocktail regimens. Individual sequences target distinct HA antigenic regions, and the patent claims describe demonstrated synergistic neutralization breadth when administered in combination — a computationally designed approach that is distinct from both chimeric HA and mRNA-encoded stalk strategies. According to NIH, NIAID has supported multiple universal influenza vaccine research programs targeting conserved antigens as part of its strategic plan for pandemic preparedness.

Yeda Research and Development Co. Ltd. patents describe synthetic flagellin-displayed peptide vaccines for intranasal delivery, incorporating B-cell HA epitopes, T-helper HA/NP epitopes, and CTL NP/M epitopes in a single construct — representing a mucosal delivery approach that is absent from the mRNA-LNP cluster.

Multivalent and Combination Respiratory Vaccine Approaches

The combination respiratory vaccine cluster — co-targeting influenza alongside SARS-CoV-2 and other pathogens — is the most geographically distributed filing cluster in the dataset, with Spicona Inc. representing the most active single filer. Combination vaccines co-targeting influenza HA/NA antigens and SARS-CoV-2 spike protein are described via multiple modality formats: live attenuated influenza virion plus live viral vector, RNA/DNA vaccine polynucleotides, and recombinant protein combinations.

BioNTech SE’s 2024 WO filing explicitly describes administering a bivalent SARS-CoV-2 RNA vaccine together with a tetravalent influenza HA mRNA vaccine to induce combined immunity. ModernaTX’s filings describe multi-mRNA combination vaccines targeting influenza A, influenza B, and up to two coronavirus strains simultaneously in LNP formulations. Instituto Butantan’s 2025 Brazilian filing describes an inactivated Newcastle disease virus (NDV) vector expressing the SARS-CoV-2 stabilized spike protein, combined with trivalent seasonal influenza antigens — produced in the same manufacturing infrastructure as seasonal influenza vaccine, a manufacturing integration strategy notable for emerging-economy contexts. According to WHO, co-administration of influenza and COVID-19 vaccines is already practiced clinically, making a co-formulated product a commercially logical next step.

Spicona Inc.’s multi-jurisdictional portfolio spans WO, CA, AU, MX, BR, CO, IL, JP, AR, GB, and US jurisdictions — all relating to the same core invention combining influenza HA/NA antigens with SARS-CoV-2 spike protein in various formats. The company’s filings describe annual re-vaccination intervals of 10–14 months, suggesting vaccine schedule modeling, though no clinical data are present in retrieved results. Developers entering this space should monitor Spicona Inc.’s portfolio alongside BioNTech and ModernaTX filings for potential interference or design-around requirements, particularly regarding HA/NA plus spike co-formulation claims.

Beyond the influenza-COVID-19 pairing, ModernaTX’s 2024 JP filing and a 2025 AU filing describe up to four or more mRNA polynucleotides in a single LNP-formulated product, targeting influenza A (multiple strains), influenza B, and coronaviruses simultaneously — a respiratory virus super-combination strategy. The octavalent and higher-valency mRNA influenza vaccines from Sanofi and University of Georgia Research Foundation represent a parallel strategy to achieve broad seasonal coverage plus cross-protective immunity from a single injection without annual strain-matching dependence. The European Medicines Agency has published guidance on combination vaccine development that will be relevant to regulatory strategy for these multi-antigen products.

Assignee Landscape, IP Density, and Strategic Implications

Patent-driven commercial innovation in the next-generation influenza vaccine space is heavily concentrated among a small number of US and European mRNA biotechs and large pharma, while academic and government institutions contribute conserved-antigen and structural biology strategies that are licensing-eligible.

Commercial Filers

ModernaTX is the most prolific influenza vaccine filer in the dataset, with patents distributed across WO, US, EP, AU, CA, IN, MX, JP, and BR jurisdictions. Claims span broad-spectrum mRNA-LNP influenza vaccines (HA head, HA2 stem, consensus sequences), seasonal mRNA influenza vaccines, and multi-pathogen respiratory combination vaccines, with filings ranging from 2017 to 2025 — indicating sustained IP expansion over nearly a decade. Competitors entering the mRNA influenza space face a dense IP landscape requiring careful freedom-to-operate analysis, as noted in PatSnap’s IP intelligence resources. Pfizer’s 2023 filings in CO and MX cover RNA vaccines encoding hemagglutinin antigens. Sanofi’s 2024 filings in MX and BR claim octavalent mRNA influenza vaccines. GlaxoSmithKline Biologicals SA spans conventional adjuvanted vaccines (2009–2011) and recent nucleic acid-based compositions (2025, AU).

Academic and Government Filers

The Trustees of the University of Pennsylvania hold a significant academic patent portfolio for nucleoside-modified mRNA-LNP universal influenza vaccines targeting HA, NA, NP, M1, and M2e, filed across WO, US, IN, NZ, AU, and BR, with filings spanning 2021–2024. The U.S. Government (represented by the Secretary of Health and Human Services/NIAID) filed patents on ferritin nanoparticle HA stem vaccines. Icahn School of Medicine at Mount Sinai is active on chimeric HA approaches (multiple IL and JP jurisdictions, 2015–2023) and nucleoside-modified mRNA universal influenza vaccines. Oregon Health and Science University and University of Pittsburgh contribute computationally optimized HA polypeptide patents covering H1N1, H3N2, H2N2, and influenza B. University of Georgia Research Foundation’s 2025 WO filings claim pentavalent and octavalent influenza immunogens.

Academic and government-affiliated organizations contribute meaningful structural and immunological innovation in conserved-antigen targeting that is licensing-eligible. Commercial developers seeking differentiated universal vaccine antigens may find partnership opportunities within these portfolios. The PatSnap Insights blog covers patent landscape analysis methodology relevant to evaluating these opportunities. Preclinical immunogenicity data cited in University of Pennsylvania patents — single-dose protection at 0.05 µg per antigen — represents a translational signal worth monitoring in forthcoming IND filings, as this dose efficiency may confer cost-of-goods and dose-sparing advantages relevant to pandemic preparedness stockpiling.

“Academic and government-affiliated organizations contribute meaningful structural and immunological innovation in conserved-antigen targeting that is licensing-eligible; commercial developers seeking differentiated universal vaccine antigens may find partnership opportunities within these portfolios.”